Summit Therapeutics Share Discussion Threads

[someuwin] 20/4/2017 13:24

I think Motif Bio (LSE:MTFB, NASDAQ:MTFB) has been mentioned here before, but after its Phase 3 trial success on Monday of iclaprim, its novel antibiotic, it must be on a clear run for approval next year and multiples of its current £77m valuation - surely?

[hugus maximus] 20/4/2017 11:53

Chris - perhaps my question is one for the AGM? In the meantime we have RDZ v FDX results to look forward to and the $22 million SRPT advance must be in soon. My above note is a question about process.

I'd hope that the share price will not sit in these particular doldrums if positive moves are announced re: C Diff.

[chrisatrdg] 19/4/2017 21:54

Following above comments today are we still on track or should we be concerned with Summits progress as reflected in the dropping share price ?

[waterloo01] 19/4/2017 17:16

Hugus, I think you are over playing and diet issues. Essentially they just have to take the drug with full fat milk. That's it. Most/all however are on steroids and weight gain is an issue especially as they get less mobile. As such I don't think absorption is much of an issue as much as the differing utrophin availability being much better with F6 than F3.

I also seem to recall they are allowing boys to stay on treatment post trial, so if you in the trial, there is continuity (and longer data to be able to assess).

All as far as I'm aware.

[hugus maximus] 19/4/2017 16:56

Waterloo ... I agree with your note about needing more boys to trial the F6 formulation in order to make a decent statistical hit.

After being fobbed off with a cancellation of the promised 24 week account of early F3 data, one can only imagine the absorption problems still create "issues" as a result of diet implementation (heaven knows - it seems a huge ask for the poor boys to endure a diet regime for 6 months ... let alone a year?)

So if superior F6 wipes the board in terms of absorption data .... why do the boys & their families risk further delays before potential approval?

Given that there must still be problems with the F3 absorption that limit the possibility of positive outcome, (this must surely be the reason to wait for F6 results before any data is made public) ... why not simply abandon the F3 now rather than waste more time and money?

Aside from any financial considerations ... I cannot imagine being a parent with a son going through a trial with F3, knowing F6 is the formulation with the true potential to change their lives.

[football] 19/4/2017 16:48

Summit Therapeutics PLC (ADR)
NASDAQ: SMMT - Apr 19, 11:32 AM EDT
10.71USDPrice decrease1.30 (10.83%)

[chrisatrdg] 19/4/2017 16:40

Recent tweet:

Summit Therapeutics‏ @Summitplc Apr 18

More

Our CEO, Glyn Edwards, is speaking at #WODC on effective license and collaboration deals in #raredisease this Thurs in Washington DC

0 replies 0 retweets 1 like
Reply Retweet
Like 1

Link:

Edit:Early signs?

[waterloo01] 19/4/2017 16:02

One would have hoped that the last patient has been dosed so the SRPT payment due soon. I'd certainly support them dosing a further 10 boys with F6, although not on the cards (?) so that when we eventually get results, we will have a statistically significant number of boys on both formulations.

Re RDZ, as we are now into a new budget year for many, any moves, be that grants or term sheets should surely be close to being decided?

[tightfist] 19/4/2017 09:20

Good to see us listed at number 2 in the list of "major players" in the DMD space; the word is spreading!

[chrisatrdg] 18/4/2017 09:24

Per Free-Money today from the other board in reply to above:

DMD PoC Study

'Yep, things ticking forward nicely and on schedule.

I was also encouraged by the increased talk of examining the potential to treat Beckers as well as Duchene.

It all adds value but PoC first, and good luck to all involved.

Next steps for us LTH's is Sarepta milestone payment and RDZ vs FDX results. Both should give the share price a kick or at least underline the value. GLA'

[chrisatrdg] 16/4/2017 21:05

Per gmcc today from the other board:

DMD PoC Study

PoC Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With DMD (PhaseOut DMD)

Note clinical trial record updated 13th April 2017 .

Recruitment status removed for all individual sites , now just a general “ This study is enrolling participants by invitation only” ! ---presumably enough patients available so SUMM can be selective ?

[chrisatrdg] 13/4/2017 14:32

Summit tweet today:

Summit Therapeutics‏ @Summitplc 43m43 minutes ago
More
Summit Therapeutics Retweeted La Force
Our patient advocacy lead, Michelle, speaks about the promise of #utrophin modulation in #Duchenne. Thx to @laforceDMD 4 posting the video!Summit Therapeutics added,2:20



Edit: Not really worth it.

[hugus maximus] 13/4/2017 14:07

MM's are definitely up to some sort of Blind Man's Poker today. Indeed FB ... I made close of business on NASDAQ a move up to around £1.86 (currant dollar / pound) And yet the opening price on AIM was a drop from around £1.77 to £1.75? The pesky imps have been doing some smoke and mirrors here since Glyn got in his Tardis last week and moved us all back a year.

[football] 13/4/2017 09:50

Didn't we finish up in the US slightly yesterday so why open up slightly down on this site of pond

[tightfist] 13/4/2017 07:43

More positively we have the EZD extension approval announced on 27th March. Unless there is news on the C.Diff front we likely need to be prepared for a possibly lengthy share price drift whilst the impatient get distracted by more immediate returns?

[luminoso] 12/4/2017 22:11

Hmmm. Fair bit of negativity here. These were options deferred from 2016 and they are " subject to achievement of performance conditions pertaining to corporate
and programme development milestones." I guess people see things differently when the share price slides a bit. Still plenty to be positive about here IMO. Share price is up 100% from lows last autumn. More cash to come from our friends at Sarepta and something likely for C Diff in summer. Yes, delays to DMD results, but no indication there is anything untoward happening in those trials. There's reasons to be nervous on the macro economic/political front, sure, but SUMM certainly not giving me sleepless nights.

[waterloo01] 12/4/2017 12:15

There not free he has to pay £1.85 (if they get exercised). Very nice if you can get them and explains why he, and the other directors don't buy any shares. They really should have some performance attached to them, and these don't, but guess if DMD fails they won't ever come into play.

[solomon] 12/4/2017 12:03

Yes, Pat, but it's not a lot of fun flying to and fro across the Atlantic to give our chums in the USA the lowdown on the investment potential of this tiny company.

[tilly99] 12/4/2017 11:18

Wow another huge slug of options for GlynGreed pure greedWhy should we be diluted again We have the science ..he's just a PR manMad amount of free options for him

[chrisatrdg] 10/4/2017 20:50

Hi All - I agree with waterloo01 in terms of his comments & sense i.e. 'the equation hasn't changed much (RDZ aside) the risk has, at least till we get closer to results.'

I am disappointed that we now need to wait to next year to have meaningful DMD results & feel that is also being reflected in the continual reduction in the share price

I also can see where HM is coming from & look forward to meeting a number of you at the next AGM but for me waiting another year after already having been invested on a accumulative basis for 7 years to go to 8 years plus is disappointing as the risk continues & all could still be lost.

I spoke to Summit the week before last before the Glyn update & sense that they are building up a strong team which is a positive but with much increased overheads.GLA.

[abergele] 10/4/2017 19:54

Yet again,the USA are calling the shots on a UK company,bahhhhh

[luminoso] 10/4/2017 19:02

Re discrepancy between AIM and NAS, the MMS are always having to second guess what the US trader chimps are going to do after AIM close. They seem to have guessed right today. But there is a caution about AIM and it is regularly below NAS these days. Sign of nerves re US markets about to correct sharply maybe ?

[waterloo01] 10/4/2017 18:57

The year end results on the surface make good reading. With the next instalment due from SRPT, Summit are cashed up till end 2018 (although not enough to fund C.diff) and have term sheets on the table re RDZ.

Having said that, A number of things in the results do rather put a dampener on it, at least in the short term. We've only recently found out that the phase 3 trials will cost about $100m (25%/50% higher than I had estimated) and while they state they have term sheets, they are obviously not compelling enough to sign on the dotted line as they are still going after charity/grant funding. Great, except I don't get why charity/grant money will come in if they have term sheets (ie funding) on the table? I also don't get the feeling, and it's no more than that, that we'll see much if any upfront given the $100m cost of the trials. I might be wrong in my interpretation, but it rather puts a dampener on RDZ for me although it might still surprise to the upside.

On ETZ, not getting an early readout and some proof of action is rather a double edged sword. I understand the reason in being able to show reliable and hopefully conclusive proof which will be huge, but it's delayed by 6 months and rather feeds doubts that Utrophin will be all we hope it will, especially in F3 part of the trial (ie 75% of boys in the trial).

I still remain hopeful (although slightly lighter share wise) and while the reward side of the equation hasn't changed much (RDZ aside) the risk has, at least till we get closer to results.